
Globus Medical (GMED) Stock Forecast & Price Target
Globus Medical (GMED) Analyst Ratings
Bulls say
Globus Medical is positioned well for above-market growth because Q1'26 showed broad-based demand, with $760MM revenue up 11.2% organic, EPS of $1.12 versus $0.92 consensus, and strong gains in U.S. Spine, trauma, and Enabling Technologies. The company’s outlook is supported by durable execution and margin expansion, as gross margin reached 69.2%, adjusted EBITDA margin was 32.3%, and management raised 2026 EPS guidance to $4.70-$4.80 while reaffirming $3.18-$3.22B in sales. Its longer-term case is strengthened by a debt-free balance sheet with $799MM cash, 30+ new product launches since fiscal 2022 close, and a robotics-led ecosystem that is driving share gains, recurring revenue opportunities, and international expansion.
Bears say
Globus Medical is facing a negative fundamental setup because its downside case depends on slower adoption of ExcelsiusGPS robotics and Excelsius3D Imaging, weaker pull-through to implants, and delayed recon robotics, all of which could constrain growth in its higher-value enabling technologies. The bear case also points to revenue growth slowing to the low-single digits with flat margins, while inflation, supply disruptions, staffing shortages, and pricing pressure threaten its industry-leading mid-70s gross margins and mid-30s operating margins. Competitive pressure from larger medtech players such as MDT, SYK, and ZBH, plus merger-related execution risk from GMED/Nuvasive, could further disrupt spine share and undermine earnings quality.
This aggregate rating is based on analysts' research of Globus Medical and is not a guaranteed prediction by Public.com or investment advice.
Globus Medical (GMED) Analyst Forecast & Price Prediction
Start investing in Globus Medical (GMED)
Order type
Buy in
Order amount
Est. shares
0 shares
FAQs About Globus Medical (GMED) Forecast
Globus Medical (GMED) Analyst Forecast & Price Prediction
Start investing in Globus Medical (GMED)
Order type
Buy in
Order amount
Est. shares
0 shares